Idec Pharmaceuticals, wrapping up a three-year site search that included theOtay Mesa area of South San Diego County as well as San Antonio, has settledon Stirling Development's 393-acre Ocean Ranch Corporate Centre, accordingto Oceanside Economic Development Director Jane McVey.

If a city incentive package is approved as expected on Wednesday, Idec wouldopen escrow on the purchase of 60 acres for the first 362,000-sf phase ofthe project, slated for completion by July 2003, McVey tells GlobeSt.com.

By 2008, the development could reach 1.37 million sf and employ up to 2,400workers, she says. The deal could put the city about 30 miles north of SanDiego on the biotechnology map, she says.

"We're very excited," McVey says. "We have a commitment to [Idec to] approvethe project very quickly."

Unlike Orange County or central San Diego County, Oceanside still has goodland availability for larger projects of 60 acres or more--at prices afraction of those areas, McVey says. Ultimately, that combination--alongwith the ready availability of purified water needed for biomedicalmanufacturing--swayed Idec's site decision.

Idec has been negotiating with the city since last October. The companyproduces the anti-lymphoma drug Rituxan, which generated nearly $100 millionin sales during the second quarter. But Idec will use the new campus todevelop and manufacture drugs that are in testing trials for futuregovernment approval.

Steven J. Bollert of Burnham Real Estate Services is representing Idec inthe land negotiations. Daniel Lnosko of the San Diego office of ColdwellBanker Commercial represents Irvine-based Stirling Development.

Continue Reading for Free

Register and gain access to:

  • Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.